5. Adjuvant therapy after SCS
35 (67.3%) patients received adjuvant chemotherapy after SCS (Table 4).
The most common chemotherapy regimen was doxorubicin-based treatment,
followed by gemcitabine/docetaxel regimen. 1 (1.9%) patient with
vaginal cuff recurrent received pelvic radiotherapy. 1
(1.9%) patient received pazopanib
treatment. 16 (30.8%) patients did not receive any adjuvant therapy
after SCS.
6. Non-secondary
cytoreductive surgery treatment
Among patients received non-secondary cytoreductive surgery treatment,
14 (73.7%) patients received
chemotherapy, 2 (10.5%) patients received chemotherapy and pelvic
radiotherapy, 1 (5.3%) patient received anlotinib treatment, and 2
(10.5%) patients refused cancer treatment (Table S1). 16 patients died
during follow-up.